Natasha Khullar, Trisha Singh, Peter O'Kane, Jonathan Hinton
{"title":"The Role of Orbital Atherectomy for Complex Coronary Calcium Modification: Has It Been Eclipsed?","authors":"Natasha Khullar, Trisha Singh, Peter O'Kane, Jonathan Hinton","doi":"10.3390/jpm15090414","DOIUrl":null,"url":null,"abstract":"<p><p>Severe coronary artery calcification (CAC) is a frequent finding in patients undergoing percutaneous coronary intervention (PCI) and represents a significant procedural challenge. CAC is commonly associated with ageing and comorbidities such as diabetes, hypertension, and chronic kidney disease, and contributes to vessel rigidity, impaired device delivery, and suboptimal stent expansion. These factors increase the risk of angiographic complications, as well as major adverse cardiac events compared with non-calcified lesions, negatively impacting both immediate and long-term clinical outcomes. In cases of severe calcification, traditional balloon angioplasty is often inadequate, necessitating the use of dedicated calcium modification techniques. Devices such as rotational atherectomy (RA), orbital atherectomy (OA), excimer laser coronary atherectomy (ELCA), and intravascular lithotripsy (IVL) have been developed to address these challenges. Among these, orbital atherectomy offers a potential unique dual mechanism of action and has shown promise in enhancing lesion preparation and facilitating optimal stent deployment. This review provides an overview of the role of orbital atherectomy in the management of calcified coronary lesions, evaluates current evidence on its safety and efficacy, and discusses how it may be positioned in the future, underscoring the need for a personalised, lesion-specific approach to optimise PCI outcomes.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471242/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15090414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Severe coronary artery calcification (CAC) is a frequent finding in patients undergoing percutaneous coronary intervention (PCI) and represents a significant procedural challenge. CAC is commonly associated with ageing and comorbidities such as diabetes, hypertension, and chronic kidney disease, and contributes to vessel rigidity, impaired device delivery, and suboptimal stent expansion. These factors increase the risk of angiographic complications, as well as major adverse cardiac events compared with non-calcified lesions, negatively impacting both immediate and long-term clinical outcomes. In cases of severe calcification, traditional balloon angioplasty is often inadequate, necessitating the use of dedicated calcium modification techniques. Devices such as rotational atherectomy (RA), orbital atherectomy (OA), excimer laser coronary atherectomy (ELCA), and intravascular lithotripsy (IVL) have been developed to address these challenges. Among these, orbital atherectomy offers a potential unique dual mechanism of action and has shown promise in enhancing lesion preparation and facilitating optimal stent deployment. This review provides an overview of the role of orbital atherectomy in the management of calcified coronary lesions, evaluates current evidence on its safety and efficacy, and discusses how it may be positioned in the future, underscoring the need for a personalised, lesion-specific approach to optimise PCI outcomes.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.